Illustration Monitoring And Treatment Of Type 1 Diabetes

Illustration Monitoring And Treatment Of Type 1 Diabetes

Box of Lantus insulin solutions produced by the Sanofi laboratory, for subcutaneous injection by pen to treat type 1 diabetes. The treatment of type 1 diabetes (called insulin-dependent diabetes) is based on subcutaneous injections of insulin, several times a day, to compensate for its lack of production by the body. June 3, 2023. Photo by Patrice Masante/ABACAPRESS.COM

  • Product Code
  • ILEA001406545
  • Registered date
  • 2023/6/03 00:00:00
  • Credit
  • Abaca Press / Kyodo News Images
  • Media source
  • Masante Patrice/ABACA
  • Media size
  • 8256 × 5504 pixel
  • Resolution
  • 300 dpi
  • Deployment size
  • 2.84(MB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Government Demands Guarantees For Doliprane Production In France

    Government Demands Guarantees For Doliprane Production In France

    Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
      Government Demands Guarantees For Doliprane Production In France

      Government Demands Guarantees For Doliprane Production In France

      Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
        Government Demands Guarantees For Doliprane Production In France

        Government Demands Guarantees For Doliprane Production In France

        Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
          Government Demands Guarantees For Doliprane Production In France

          Government Demands Guarantees For Doliprane Production In France

          Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
            Government Demands Guarantees For Doliprane Production In France

            Government Demands Guarantees For Doliprane Production In France

            Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
              Government Demands Guarantees For Doliprane Production In France

              Government Demands Guarantees For Doliprane Production In France

              Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                Government Demands Guarantees For Doliprane Production In France

                Government Demands Guarantees For Doliprane Production In France

                Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                  Government Demands Guarantees For Doliprane Production In France

                  Government Demands Guarantees For Doliprane Production In France

                  Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                    Government Demands Guarantees For Doliprane Production In France

                    Government Demands Guarantees For Doliprane Production In France

                    Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM
                      Government Demands Guarantees For Doliprane Production In France

                      Government Demands Guarantees For Doliprane Production In France

                      Illustrations Doliprane on October 15, 2024. The French laboratory Sanofi announced on October 4 that it wanted to sell part of its subsidiary Opella, which produces generic drugs such as Doliprane, to an American fund, the American investment fund CD-R. On Wednesday, the French Health Minister called for guarantees that Doliprane would be “produced in France”, that pharmacies would receive “normal supplies” and that “sufficient stocks” would be available. Photo by Jean Pierre Nguyen Van Hai Barbier/ABACAPRESS.COM